# An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

> **NCT05451056** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 37 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** sotorasib

## Key facts

- **NCT ID:** NCT05451056
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2026-01
- **Final completion:** 2026-02
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451056, "An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05451056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*